AMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE
|
|
- Bethanie Rich
- 5 years ago
- Views:
Transcription
1 AMRI COMPOUD LIBRARY COSORTIUM: A OVEL WAY TO FILL YOUR DRUG PIPELIE Muralikrishna Valluri, PhD & Douglas B. Kitchen, PhD Summary The creation of high-quality, innovative small molecule leads is a continual challenge in drug discovery. Against a background of increasing cost, the rate of drug discovery has remained stagnant for over 60 years. Improving research and development productivity is a considerable obstacle for the pharmaceutical sector. To address these challenges, innovative methods are crucial. High-throughput screening (HTS) is a major cornerstone of drug discovery; however, the availability of an innovative, relevant and high-quality compound collection for screening often dictates the fate of a drug discovery campaign. Given that the chemical space to be sampled in research programs is vast and sparsely populated, significant resources need to be invested to generate and maintain a competitive compound collection. By leveraging diverse experience and industrial expertise in synthetic and medicinal chemistry, AMRI addresses this challenge in a novel way through the Compound Library Consortium (CLC). Inadequacies of Combinatorial Chemistry and Small Molecule Libraries While revolutionary in the 1990s, combinatorial chemistry as a means for rapidly increasing the rate of new drugs in development has proven largely ineffective. However, instead of being abandoned, combinatorial chemistry has evolved, and large compound libraries are being enhanced with smaller, targeted libraries. Even so, large combinatorial libraries that were cost-efficient supplements to collections cannot increase the diversity of chemotypes to address new biological mechanisms, and existing small molecule collections are not adequate to generate viable leads. AMRI has evolved its chemical library synthesis offerings to address both the cost and diversity of libraries. Discovering the Best Candidate Rather than taking an indiscriminate approach to producing large numbers of compounds to high-throughput screening collections, the emphasis of the AMRI-led CLC is on synthesizing the right compounds, purifying them to >90% purity, and designing them for diverse targets. Leads are optimized by making small changes in the chemical structure that affect its physicochemical properties, toxicology, potency and binding interactions all key elements in finding a compound with the best chance of providing quality leads suitable for lead optimization activities. Figure 1. Consortium process Scaffold Ideas (AMRI & CLC Members) Analysis, Data Transfer & Shipment by AMRI Distribution to CLC Members for Selection Library Chemistry Validation, Production & Purification by AMRI Scaffold Selection by CLC Members & Chemistry Validation/Synthesis by AMRI Template Design by AMRI & Distribution to CLC Members for Selection Template Synthesis, Virtual Library Enumeration & Distribution of Libraries to CLC Members for Selection
2 About the CLC AMRI will prepare and deliver 70,000 compounds in approximately equal sets quarterly over 2.5 to 3 years. Cost-sharing among multiple members reduces the cost of compounds well below typical market prices. Members receive 2 mg of each lead-like compound, 25 mg of each fragment-like compound with each having >90% purity (LC/MS and 10% by 1H MR data provided). Scaffold libraries range in size from ca members/scaffold to maximize diversity. CLC members may file patent applications on compounds in CLC and additional analogs derived from them. Role of the Joint Consortium Committee (JCC) and the Consortium Process Each member company there are currently three has a representative on the Joint Consortium Committee, chaired by AMRI. The JCC is responsible for the general review and monitoring of the CLC s activities. The JCC oversees the designation of scaffolds, templates and final compounds to be synthesized for the CLC. The JCC is involved in proposing, reviewing, approving and amending CLC strategies for the upcoming delivery periods. Quarterly JCC meetings are held and additional teleconferences scheduled as needed. Synthetic Process Ensures Diversity AMRI has designed a set of distinct scaffold cores for the CLC library, starting from interesting scaffolds that are underrepresented in patent and medicinal chemistry literature. Approximately 1,000 distinct scaffold ideas have been designed by AMRI medicinal chemists and are available to the CLC. Every scaffold contains 2-3 points of diversity where the scaffold structure becomes the starting material for 5-10 chemical structures, which we term templates. See Figure 2 for a few representative structures of scaffolds. Templates need to be diverse within a scaffold to achieve a truly diverse parallel library, and scaffold intermediates must be synthesized at the 100 gm scale. Each template elaborates one or two points of diversity such that it can then be used as starting material for relatively small parallel libraries. We continually investigate additional conditions to achieve diverse parallel library chemistry. Figure 2. Representative structures The current parallel chemistry available: Amide formation Sulfonamide Reductive amination Alkylations Mitsunobu Urea formation Suzuki Buchwald SAr Click chemistry Physical Properties of the Compound Library Two factors create unique diversity of the CLC scaffold and template selection and the limitation of the number of analogs to a maximum of ca. 200 per scaffold. In addition: All libraries are designed to produce lead-like hits as exemplified in the acceptable ranges of physical and constitutive properties (see Table 1). Approximately 1-2 percent of compounds are expected to be fragment-like, obeying the rule of 3. In all cases, reactive compounds are excluded and compounds will pass mutually agreed pan assay interference compounds (PAIS) structural alerts. Libraries are designed to consist of compounds with a high degree of three-dimensional structure. H H OH R Table 1. Key properties monitored Property Lead-Like Acceptable Range Fragment-Like Acceptable Range MW <450 <350 clogp <3.5 tpsa umber of rings 5 <3 umber of aromatic rings 3 <2 Rotatable bonds 8
3 AMRI maximizes 3-D structure in two ways. First, a high fraction of sp3 carbons centers (Fsp3) is desirable in each compound. An average target is set at 0.4. By using scaffolds and templates with high Fsp3, the parallel library step can use aromatic R-groups, which can simplify the library chemistry. Second, AMRI calculates the principal moments of inertia of each compound. Plotting the relative components of the PMI of a compound allows it to be characterized as sphere-like, rod-like and disk-like. Spheres have three nearly equal dimensions, a disk has two nearly equal dimensions and a rod has effectively only one dimension. 2 The introduction of a large number of sp3 carbon centers can introduce stereochemistry into a molecule. Therefore, we have determined that racemic mixtures are acceptable while mixtures of diastereoisomers are avoided. Only single enantiomers are catalogued if there are two or more stereo centers. In Figure 3, we illustrate the distributions of these properties on approximately 27,000 compounds completed as part of the current CLC. In general, we have been able to keep all properties within acceptable ranges with few exceptions. Figure 4 illustrates that the compounds are generally diverse amongst themselves. Half of all compounds have no nearest neighbor with a Tanimoto coefficient greater than 0.7 in spite of the fact that all compounds share common templates and scaffolds with many other compounds (often analogs per template). The relatively large number of identical compounds is due to the fact that we have been able to provide enantiomerically pure example of two stereoisomers. Finally, Figure 5 illustrates that the synthesized compounds have a reasonable 3D diversity as well. The shapes primarily span rod-like and disk-like molecules however, a significant number are best described as spheres. Figure 3: Distribution of several key properties in 27,000 synthesized compounds from CLC X Axis: Range for the property Y Axis: Percent of 27,000 compounds Molecular Weight clogp tpsa
4 Figure 4: Distribution of maximum pairwise similarities, demonstrating compounds diversity X Axis: Value of maximum pairwise Tanimoto coefficient to each compound (similarity calculated using Morgan fingerprints as implemented in RdKit; see RdKit.org) Y Axis: Percentage composition of library Distribution of Max Similarity Pairs PMI: ormalized Components Figure 5: ormalized principal moments of inertia: A measure of 3D diversity PR1 and PR2: Principal moment of inertia normalized for each molecule by dividing each axis by the longest axis of the molecule. Shapes primarily span rod-like and disk-like molecules; however, a significant number are sphere-like.
5 About AMRI AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in orth America, Europe and Asia, AMRI s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit 1 Fsp3 = sp3 carbons / total carbons 2 Sauer, WHB, Schwarz, MK; Molecular shape diversity of combinatorial libraries: A prerequisite for broad bioactivity. J Chem Inf Comput Sci 2003, 43, Discovery Development Analytical and Solid State Services API Manufacturing Drug Product
Design and Synthesis of the Comprehensive Fragment Library
YOUR INNOVATIVE CHEMISTRY PARTNER IN DRUG DISCOVERY Design and Synthesis of the Comprehensive Fragment Library A 3D Enabled Library for Medicinal Chemistry Discovery Warren S Wade 1, Kuei-Lin Chang 1,
More informationCOMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE
NUE FEATURE T R A N S F O R M I N G C H A L L E N G E S I N T O M E D I C I N E Nuevolution Feature no. 1 October 2015 Technical Information COMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE A PROMISING
More informationCONTINUOUS FLOW CHEMISTRY (PROCESSING) FOR INTERMEDIATES AND APIs
CONTINUOUS FLOW CHEMISTRY (PROCESSING) FOR INTERMEDIATES AND APIs Sripathy Venkatraman, Section Head at AMRI Abstract Many contract manufacturing organizations (CMOs) offer continuous flow chemistry, but
More informationEnamine Golden Fragment Library
Enamine Golden Fragment Library 14 March 216 1794 compounds deliverable as entire set or as selected items. Fragment Based Drug Discovery (FBDD) [1,2] demonstrates remarkable results: more than 3 compounds
More informationImportant Aspects of Fragment Screening Collection Design
Important Aspects of Fragment Screening Collection Design Phil Cox, Ph. D., Discovery Chemistry and Technology, AbbVie, USA Cresset User Group Meeting, Cambridge UK. Thursday, June 29 th 2017 Disclosure-
More informationChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)
ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD) CEMDIV BEYD TE FLATLAD 3D-FRAGMET LIBRARY BACKGRUD Fragment-based drug discovery (FBDD) has become an efficient
More informationAutomated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity. Darren Green GSK
Automated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity Darren Green GSK The Compound Collection Enhancement Challenge A diversity of ideas Which are novel Which have the desired
More informationUnlocking the potential of your drug discovery programme
Unlocking the potential of your drug discovery programme Innovative screening The leading fragment screening platform with MicroScale Thermophoresis at its core Domainex expertise High quality results
More informationIntroduction. OntoChem
Introduction ntochem Providing drug discovery knowledge & small molecules... Supporting the task of medicinal chemistry Allows selecting best possible small molecule starting point From target to leads
More informationCOMBINATORIAL CHEMISTRY: CURRENT APPROACH
COMBINATORIAL CHEMISTRY: CURRENT APPROACH Dwivedi A. 1, Sitoke A. 2, Joshi V. 3, Akhtar A.K. 4* and Chaturvedi M. 1, NRI Institute of Pharmaceutical Sciences, Bhopal, M.P.-India 2, SRM College of Pharmacy,
More informationReaxys Improved synthetic planning with Reaxys
R&D SOLUTIONS Reaxys Improved synthetic planning with Reaxys Integration of custom inventory and supplier catalogs in Reaxys helps chemists overcome challenges in planning chemical synthesis due to the
More informationThe Case for Use Cases
The Case for Use Cases The integration of internal and external chemical information is a vital and complex activity for the pharmaceutical industry. David Walsh, Grail Entropix Ltd Costs of Integrating
More informationIgnasi Belda, PhD CEO. HPC Advisory Council Spain Conference 2015
Ignasi Belda, PhD CEO HPC Advisory Council Spain Conference 2015 Business lines Molecular Modeling Services We carry out computational chemistry projects using our selfdeveloped and third party technologies
More informationEMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS
EMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS PETER GUND Pharmacopeia Inc., CN 5350 Princeton, NJ 08543, USA pgund@pharmacop.com Empirical and theoretical approaches to drug discovery have often
More informationFor Excellence in Organic Chemistry
Organix Inc. Your Contract Research and Custom Synthesis Company www.organixinc.com For Excellence in Organic Chemistry Organix Inc. A Contract Research and Custom Synthesis Company At the discovery end
More informationEarly Stages of Drug Discovery in the Pharmaceutical Industry
Early Stages of Drug Discovery in the Pharmaceutical Industry Daniel Seeliger / Jan Kriegl, Discovery Research, Boehringer Ingelheim September 29, 2016 Historical Drug Discovery From Accidential Discovery
More informationHit Finding and Optimization Using BLAZE & FORGE
Hit Finding and Optimization Using BLAZE & FORGE Kevin Cusack,* Maria Argiriadi, Eric Breinlinger, Jeremy Edmunds, Michael Hoemann, Michael Friedman, Sami Osman, Raymond Huntley, Thomas Vargo AbbVie, Immunology
More informationChemical library design
Chemical library design Pavel Polishchuk Institute of Molecular and Translational Medicine Palacky University pavlo.polishchuk@upol.cz Drug development workflow Vistoli G., et al., Drug Discovery Today,
More informationReturn on Investment in Discovery Chiral Separations
Return on Investment in Discovery Chiral Separations Averica Discovery Services 260 Cedar Hill Street Marlborough MA 01752 www.avericadiscovery.com @averica_feed What Should I Spend? Understanding ROI
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract research
More informationGyörgy M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences
Fragment based lead discovery - introduction György M. Keserű H2020 FRAGET etwork Hungarian Academy of Sciences www.fragnet.eu Hit discovery from screening Druglike library Fragment library Large molecules
More informationReaxys Medicinal Chemistry Fact Sheet
R&D SOLUTIONS FOR PHARMA & LIFE SCIENCES Reaxys Medicinal Chemistry Fact Sheet Essential data for lead identification and optimization Reaxys Medicinal Chemistry empowers early discovery in drug development
More informationThe use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration
The use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration Chris Luscombe, Computational Chemistry GlaxoSmithKline Summary of Talk Traditional approaches SAR Free-Wilson
More informationIn Silico Investigation of Off-Target Effects
PHARMA & LIFE SCIENCES WHITEPAPER In Silico Investigation of Off-Target Effects STREAMLINING IN SILICO PROFILING In silico techniques require exhaustive data and sophisticated, well-structured informatics
More informationBuilding innovative drug discovery alliances. Just in KNIME: Successful Process Driven Drug Discovery
Building innovative drug discovery alliances Just in KIME: Successful Process Driven Drug Discovery Berlin KIME Spring Summit, Feb 2016 Research Informatics @ Evotec Evotec s worldwide operations 2 Pharmaceuticals
More informationRECENT TRENDS IN PHARMACEUTICAL CHEMISTRY FOR DRUG DISCOVERY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Review Article RECENT TRENDS IN PHARMACEUTICAL CHEMISTRY FOR DRUG DISCOVERY Sathyaraj A Department of Chemistry,
More informationData Mining in the Chemical Industry. Overview of presentation
Data Mining in the Chemical Industry Glenn J. Myatt, Ph.D. Partner, Myatt & Johnson, Inc. glenn.myatt@gmail.com verview of presentation verview of the chemical industry Example of the pharmaceutical industry
More informationBiologically Relevant Molecular Comparisons. Mark Mackey
Biologically Relevant Molecular Comparisons Mark Mackey Agenda > Cresset Technology > Cresset Products > FieldStere > FieldScreen > FieldAlign > FieldTemplater > Cresset and Knime About Cresset > Specialist
More informationThe shortest path to chemistry data and literature
R&D SOLUTIONS Reaxys Fact Sheet The shortest path to chemistry data and literature Designed to support the full range of chemistry research, including pharmaceutical development, environmental health &
More informationSince 1988 High Force Research has worked with organizations operating in practically all end use sectors requiring chemical synthesis input, and
Since 1988 High Force Research has worked with organizations operating in practically all end use sectors requiring chemical synthesis input, and offers a range of services allied to new product development
More informationChemical Space. Space, Diversity, and Synthesis. Jeremy Henle, 4/23/2013
Chemical Space Space, Diversity, and Synthesis Jeremy Henle, 4/23/2013 Computational Modeling Chemical Space As a diversity construct Outline Quantifying Diversity Diversity Oriented Synthesis Wolf and
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Design of screening projects General remarks Introduction Screening is done to identify new chemical substances against molecular mechanisms of a disease It is a question of
More informationChiroSolve Enantiomer preparation for discovery, development and manufacturing
ChiroSolve Enantiomer preparation for discovery, development and manufacturing Presenter: Dr. Niteen A. Vaidya CTO, ChiroSolve Inc. 2065 Martin Ave. suite 107, Santa Clara, CA 95050 Telephone: (408) 834-8597
More informationVirtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME
Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME Iván Solt Solutions for Cheminformatics Drug Discovery Strategies for known targets High-Throughput Screening (HTS) Cells
More informationIntroduction to Chemoinformatics and Drug Discovery
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013 The Chemical Space There are atoms and space. Everything else is opinion. Democritus (ca.
More informationDivCalc: A Utility for Diversity Analysis and Compound Sampling
Molecules 2002, 7, 657-661 molecules ISSN 1420-3049 http://www.mdpi.org DivCalc: A Utility for Diversity Analysis and Compound Sampling Rajeev Gangal* SciNova Informatics, 161 Madhumanjiri Apartments,
More informationFall Organic Chemistry Experiment #6 Fractional Crystallization (Resolution of Enantiomers)
Suggested Reading: Fall Organic Chemistry Experiment #6 Fractional Crystallization (Resolution of Enantiomers) Jones Section 4.9 Physical Properties of Diastereomers: Optical Resolution pages 176-178 Introduction
More informationYour Partner for Specialty Chemical Innovation & Technology
CORPORATE OVERVIEW Your Partner for Specialty Chemical Innovation & Technology CORPORATE OVERVIEW OUR COMPANY GROWTH MPD Chemicals is a US-based manufacturer of custom and specialty chemicals with over
More informationCHEMISTRY (CHE) CHE 104 General Descriptive Chemistry II 3
Chemistry (CHE) 1 CHEMISTRY (CHE) CHE 101 Introductory Chemistry 3 Survey of fundamentals of measurement, molecular structure, reactivity, and organic chemistry; applications to textiles, environmental,
More informationCheminformatics Role in Pharmaceutical Industry. Randal Chen Ph.D. Abbott Laboratories Aug. 23, 2004 ACS
Cheminformatics Role in Pharmaceutical Industry Randal Chen Ph.D. Abbott Laboratories Aug. 23, 2004 ACS Agenda The big picture for pharmaceutical industry Current technological/scientific issues Types
More informationUsing AutoDock for Virtual Screening
Using AutoDock for Virtual Screening CUHK Croucher ASI Workshop 2011 Stefano Forli, PhD Prof. Arthur J. Olson, Ph.D Molecular Graphics Lab Screening and Virtual Screening The ultimate tool for identifying
More informationKNIME-based scoring functions in Muse 3.0. KNIME User Group Meeting 2013 Fabian Bös
KIME-based scoring functions in Muse 3.0 KIME User Group Meeting 2013 Fabian Bös Certara Mission: End-to-End Model-Based Drug Development Certara was formed by acquiring and integrating Tripos, Pharsight,
More informationEuropean Lead Factory Web Portal Successful operation 3 years on
Tim Dudgeon European Lead Factory Web Portal Successful operation 3 years on About ELF Part of the Innovative Medicines Initiative www.europeanleadfactory.eu IMI supports collaborative research projects
More informationIntroduction to FBDD Fragment screening methods and library design
Introduction to FBDD Fragment screening methods and library design Samantha Hughes, PhD Fragments 2013 RSC BMCS Workshop 3 rd March 2013 Copyright 2013 Galapagos NV Why fragment screening methods? Guess
More informationChemically Intelligent Experiment Data Management
Chemically Intelligent Experiment Data Management Offering tools specifically designed to optimize the workflow of synthetic, medicinal, process and analytical chemists, the E-WorkBook Suite delivers a
More informationMDL Databases. Solutions At Every Stage in the R&D Process. MDL Databases. Information Systems, Inc.
MDL Databases Solutions At Every Stage in the R&D Process MDL Databases Information Systems, Inc. Solutions At Every Stage in the R&D Process MDL Databases Many of the problems scientists encounter during
More informationNew Synthetic Technologies in Medicinal Chemistry
New Synthetic Technologies in Medicinal Chemistry Edited by Elizabeth Farrant Worldwide Medicinal Chemistry, Pfizer Ltd., Sandwich, Kent, UK Chapter 1 Chapter 2 Introduction Elizabeth Farrant 1.1 Introduction
More informationNavigation in Chemical Space Towards Biological Activity. Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland
Navigation in Chemical Space Towards Biological Activity Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland Data Explosion in Chemistry CAS 65 million molecules CCDC 600 000 structures
More informationCOMPUTERS IN PHARMACEUTICAL RESEARCH & DEVELOPMENT
COMPUTERS IN PHARMACEUTICAL RESEARCH & DEVELOPMENT Presented by MrsA. Lavanya M.Pharm., Assistant Professor Department of Pharmaceutics Krishna Teja Pharmacy college Subject; Computer Aided Drug Delivery
More informationIntermediates. THF Solutions. Expanded Tetrahydrofuran Offer for Pharma Customers in Europe
Intermediates THF Solutions Expanded Tetrahydrofuran Offer for Pharma Customers in Europe BASF We create chemistry About BASF At BASF, we create chemistry and have been doing so for 150 years. Our portfolio
More information10/18/2006. Biotage A Life Science Technology Company
10/18/2006 Biotage A Life Science Technology Company About Biotage Headquartered in Uppsala, Sweden Three Centers of Excellence Uppsala, Sweden Research & Development Charlottesville VA, U.S.A. Instrument
More informationAn automated synthesis programme for drug discovery
An automated synthesis programme for drug discovery Automation has revolutionised the way that organic synthesis is performed in the research laboratory. Dr James Harness, Bohdan Automation Inc Combinatorial
More informationFragment-based de novo Design
ragment-based de novo Design Gisbert Schneider & Uli echner gisbert.schneider@modlab.de www.modlab.de Beilstein Endowed Chair for Cheminformatics Institute of rganic Chemistry & Chemical Biology Johann
More informationSARA Pharm Solutions
SARA Pharm Solutions Who we are? Sara Pharm Solutions European Innovative R&D-based Solid state pharmaceutical CRO 2 Company Background Incorporated in Bucharest, Romania Contract Research Organization
More informationComputational chemical biology to address non-traditional drug targets. John Karanicolas
Computational chemical biology to address non-traditional drug targets John Karanicolas Our computational toolbox Structure-based approaches Ligand-based approaches Detailed MD simulations 2D fingerprints
More informationComputational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007
Computational Chemistry in Drug Design Xavier Fradera Barcelona, 17/4/2007 verview Introduction and background Drug Design Cycle Computational methods Chemoinformatics Ligand Based Methods Structure Based
More informationLIBRARY DESIGN FOR COLLABORATIVE DRUG DISCOVERY: EXPANDING DRUGGABLE CHEMOGENOMIC SPACE
5 th /June/2018@British Embassy in Tokyo LIBRARY DESIGN FOR COLLABORATIVE DRUG DISCOVERY: EXPANDING DRUGGABLE CHEMOGENOMIC SPACE Kazuyoshi Ikeda, Ph.D. Keio University SELF-INTRODUCTION Keio University,
More informationThe Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company. Sally Rose BioFocus plc
The Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company Sally Rose BioFocus plc Overview History of BioFocus and acquisition of CDD Biological
More informationIntroducing a Bioinformatics Similarity Search Solution
Introducing a Bioinformatics Similarity Search Solution 1 Page About the APU 3 The APU as a Driver of Similarity Search 3 Similarity Search in Bioinformatics 3 POC: GSI Joins Forces with the Weizmann Institute
More informationKalexsyn Overview Kalexsyn, Inc Campus Drive Kalamazoo, MI Phone: (269) Fax: (269)
Kalexsyn verview 2017 Kalexsyn, Inc. 4502 Campus Drive Kalamazoo, MI 49008 Phone: (269) 488-8488 Fax: (269) 488-8490 info@kalexsyn.com What we are Experienced medicinal chemists Conception and synthesis
More informationChemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, NJ, (USA) Table of Contents
Electronic Supplementary Material (ESI) for Green Chemistry. This journal is The Royal Society of Chemistry 2016 S1 Supporting Information A Data-Driven Strategy for Predicting Greenness Scores, Rationally
More informationSolution Story: Dr. Carsten Schauerte, Managing Director of solid-chem GmbH
Reaxys CHEMICAL R&D Solution Story: Dr. Carsten Schauerte, Managing Director of solid-chem GmbH Reaxys meets the property data needs for effective analytics, saving time and advancing scientific work Summary
More informationIntermediates. The broadest portfolio of vinyl monomers
Intermediates The broadest portfolio of vinyl monomers BASF The Chemical Company BASF is the world s leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance
More informationAn Integrated Approach to in-silico
An Integrated Approach to in-silico Screening Joseph L. Durant Jr., Douglas. R. Henry, Maurizio Bronzetti, and David. A. Evans MDL Information Systems, Inc. 14600 Catalina St., San Leandro, CA 94577 Goals
More informationUse of data mining and chemoinformatics in the identification and optimization of high-throughput screening hits for NTDs
Use of data mining and chemoinformatics in the identification and optimization of high-throughput screening hits for NTDs James Mills; Karl Gibson, Gavin Whitlock, Paul Glossop, Jean-Robert Ioset, Leela
More informationPerseverance. Experimentation. Knowledge.
2410 Intuition. Perseverance. Experimentation. Knowledge. All are critical elements of the formula leading to breakthroughs in chemical development. Today s process chemists face increasing pressure to
More informationPharma and Suppliers: Collaborating on Green Chemistry. Launch of PMI tool. ACS Green Chemistry Institute Pharmaceutical Roundtable
Pharma and Suppliers: Collaborating on Green Chemistry. Launch of PMI tool ACS Green Chemistry Institute Pharmaceutical Roundtable Dave Hughes 08-Feb-2011 2011 Copyright American Chemical Society Green
More informationMicrowave Energy in Accelerating Reaction Rate of Solid-Assisted Solution Phase Synthesis
Microwave Energy in Accelerating Reaction Rate of Solid-Assisted Solution Phase Synthesis Shahnaz Ghassemi, Discovery Chemistry Group1725 Discovery Drive Charlottesville, VA 22911 Introduction Solid-Assisted
More informationBIOVIA ENHANCED STEREOCHEMICAL REPRESENTATION WHITE PAPER
BIOVIA ENHANCED STEREOCHEMICAL REPRESENTATION WHITE PAPER THE CHALLENGE Applied synthetic chemistry has been placing increasing emphasis in recent years on stereochemistry. In the pharmaceutical industry,
More informationt Making Pharma Greener:
ACS Green Chemistry Institute t Making Pharma Greener: 5Years of the ACS GCI Pharmaceutical Roundtable Buzz Cue ACS Green Chemistry Institute Governing Board 1155 Sixteenth Street, NW, Washington, DC 20036
More informationStatistical concepts in QSAR.
Statistical concepts in QSAR. Computational chemistry represents molecular structures as a numerical models and simulates their behavior with the equations of quantum and classical physics. Available programs
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery chemicals Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract
More informationChromegaChiral TM Columns. The right choice for chiral purification
ChromegaChiral TM Columns The right choice for chiral purification Chiral Chromatography The Background... 01 Chiral Stationary Phases (CSP) and Chirality Comparison of Chiral and Achiral Molecules. (a)
More informationDr. Heekyung BAE WED.
Dr. Heekyung BAE 2018. 1. 24. WED. 1. Background 2. Objectives and Contents 3. Consortium 4. Progress with Overseas Institutions 1. Background : Needs of Domestic Nano-companies Recently, in the "Nanotechnology
More informationForm 0 CHE321 Exam 1 9/26/2006
CE321 Exam 1 9/26/2006 Multiple Choice Questions. 60 points 1. Draw the two best contributing structures for methylimidate. To get you started a partial structure is given. C C C Choose the incorrect statement.
More informationApplications of Fragment Based Approaches
Applications of Fragment Based Approaches Ben Davis Vernalis R&D, Cambridge UK b.davis@vernalis.com 1 Applications of Fragment Based Approaches creening fragment libraries Techniques Vernalis eeds approach
More informationIntermediates. The broadest portfolio of vinyl monomers
Intermediates The broadest portfolio of vinyl monomers BASF We create Chemistry At BASF, we create chemisty. Our portfolio ranges from chemicals, plastics, performance products and crop protection products
More informationAssessing Synthetic Accessibility of Chemical Compounds Using Machine Learning Methods
J. Chem. Inf. Model. 2010, 50, 979 991 979 Assessing Synthetic Accessibility of Chemical Compounds Using Machine Learning Methods Yevgeniy Podolyan, Michael A. Walters, and George Karypis*, Department
More informationBioorganic & Medicinal Chemistry
Bioorganic & Medicinal Chemistry 20 (2012) 5324 5342 Contents lists available at SciVerse ScienceDirect Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc Early phase drug discovery:
More informationThe Comprehensive Report
High-Throughput Screening 2002: New Strategies and Technologies The Comprehensive Report Presented by HighTech Business Decisions 346 Rheem Blvd., Suite 208, Moraga, CA 94556 Tel: (925) 631-0920 Fax: (925)
More informationWelcome to Week 5. Chapter 9 - Binding, Structure, and Diversity. 9.1 Intermolecular Forces. Starting week five video. Introduction to Chapter 9
Welcome to Week 5 Starting week five video Please watch the online video (49 seconds). Chapter 9 - Binding, Structure, and Diversity Introduction to Chapter 9 Chapter 9 contains six subsections. Intermolecular
More informationRetrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a
Retrieving hits through in silico screening and expert assessment M.. Drwal a,b and R. Griffith a a: School of Medical Sciences/Pharmacology, USW, Sydney, Australia b: Charité Berlin, Germany Abstract:
More informationInstitute of Organic Chemistry with Centre of Phytochemistry Bulgarian Academy of Sciences
Institute of Organic Chemistry with Centre of Phytochemistry Bulgarian Academy of Sciences Institute of Organic Chemistry with Centre of Phytochemistry The Institute was established in 1960. The Centre
More informationHow IJC is Adding Value to a Molecular Design Business
How IJC is Adding Value to a Molecular Design Business James Mills Sexis LLP ChemAxon TechTalk Stevenage, ov 2012 james.mills@sexis.co.uk Overview Introduction to Sexis Sexis IJC use cases Data visualisation
More informationOctober 6 University Faculty of pharmacy Computer Aided Drug Design Unit
October 6 University Faculty of pharmacy Computer Aided Drug Design Unit CADD@O6U.edu.eg CADD Computer-Aided Drug Design Unit The development of new drugs is no longer a process of trial and error or strokes
More informationComputational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004
Computational Methods and Drug-Likeness Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004 The Problem Drug development in pharmaceutical industry: >8-12 years time ~$800m costs >90% failure
More informationRecent Advances to Improve Chemical Development
Recent Advances to Improve Chemical Development Agenda Challenges in Today s Pharma Industry Industry Drivers for Change Four Ways to Improve Organic Synthesis Enabling Technology Impact of New Tools on
More informationJEFFERSON COLLEGE COURSE SYLLABUS CHM200 ORGANIC CHEMISTRY I. 5 Credit Hours. Prepared by: Richard A. Pierce
JEFFERSON COLLEGE COURSE SYLLABUS CHM200 ORGANIC CHEMISTRY I 5 Credit Hours Prepared by: Richard A. Pierce Revised Date: January 2008 by Ryan H. Groeneman Arts & Science Education Dr. Mindy Selsor, Dean
More informationCapturing Chemistry. What you see is what you get In the world of mechanism and chemical transformations
Capturing Chemistry What you see is what you get In the world of mechanism and chemical transformations Dr. Stephan Schürer ead of Intl. Sci. Content Libraria, Inc. sschurer@libraria.com Distribution of
More informationCH MEDICINAL CHEMISTRY
CH 458 - MEDICINAL CHEMISTRY SPRING 2011 M: 5:15pm-8 pm Sci-1-089 Prerequisite: Organic Chemistry II (Chem 254 or Chem 252, or equivalent transfer course) Instructor: Dr. Bela Torok Room S-1-132, Science
More informationDiscovering The World Of Chemistry
Discovering The World Of Chemistry Dr. Dimitrios Tzalis IMI Open Info Day: Horizon 2020 - Health, demographic change and wellbeing 18th September 2015 Brussel Taros Chemicals GmbH & Co. KG Taros: Stability,
More informationDe Novo molecular design with Deep Reinforcement Learning
De Novo molecular design with Deep Reinforcement Learning @olexandr Olexandr Isayev, Ph.D. University of North Carolina at Chapel Hill olexandr@unc.edu http://olexandrisayev.com About me Ph.D. in Chemistry
More informationUsing Design of Experiments to Optimize Chiral Separation
1 of 7 10/5/2010 1:15 PM Home About us Guidance e-newsletter Expert Insights Readers' Choice Resources Audio & Video» QbD News Categorized Expert Insights, Resources Using Design of Experiments to Optimize
More informationCHEM 240: Survey of Organic Chemistry at North Dakota State University Midterm Exam 02 - Tue, 23 Sep 2014!! Name:! KEY!
CEM 240: Survey of rganic Chemistry at orth Dakota State University Midterm Exam 02 - Tue, 23 Sep 2014!! ame:! KEY! Please read through each question carefully and answer in the spaces provided. A good
More informationChemistry 11. Unit 10 Organic Chemistry Part I Introduction
Chemistry 11 Unit 10 Organic Chemistry Part I Introduction 2 1. Prelude In this chapter we will be looking at organic chemistry. By definition, organic chemistry is the study of structure, properties and
More informationIncreasing the Coverage of Medicinal Chemistry-Relevant Space in Commercial Fragments Screening
pubs.acs.org/jcim Increasing the Coverage of Medicinal Chemistry-Relevant Space in Commercial Fragments Screening N. Yi Mok,, Ruth Brenk,*,,# and Nathan Brown*, Cancer Research UK Cancer Therapeutics Unit,
More informationThe Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL
The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL PROJECT DETAILS Project Title: Design and synthesis of libraries of bifunctional degraders for the discovery of new cancer targets SUPERVISORY
More informationGreen Chemistry & Engineering for Pharmacuetical Industry Impact of Process Research / Route Scouting towards the Environment during API Life Cycle
Green Chemistry & Engineering for Pharmacuetical Industry Impact of Process Research / Route Scouting towards the Environment during API Life Cycle Dhileep Krishnamurthy, Ph.D. Outline Introduction Green
More informationReceptor Based Drug Design (1)
Induced Fit Model For more than 100 years, the behaviour of enzymes had been explained by the "lock-and-key" mechanism developed by pioneering German chemist Emil Fischer. Fischer thought that the chemicals
More informationDr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre
Dr. Sander B. Nabuurs Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre The road to new drugs. How to find new hits? High Throughput
More information